冠心病具有起病急、死亡率高的特点。冠心病的主要病理基础是不稳定粥样硬化斑块,临床亟需能够寻求早期、无创、简便及准确检测冠状动脉粥样硬化斑块的标志物。代谢组学是对生物体系(细胞、组织或生物体)中所有小分子质量代谢物进行定性定量分析的新兴的重要组学技术;近年来在心血管疾病中的应用研究受到很大关注,通过全面定量定性分析心血管疾病患者及模型样本中多种小分子物质,来研究生物体受内、外环境干扰后其内源性代谢物质的变化及其规律,寻找到与疾病相关的代谢标志物群,为疾病的早期诊断、早期干预提供新思路、新途径。作者分别就代谢组学在描述冠状动脉疾病发展状态、数据处理方法、代谢标志物群、探索疾病发病原因和发病机理等几个方面的应用及进展进行回顾和综述,并对其发展前景进行展望。

[1] BASAK T,VARSHNEY S,HAMID Z,et al.Identification of metabolic markers in coronary artery disease using an untargeted LC-MS based metabolomic approach[J].Journal of Proteomics,2015,127(Pt A):169-177.
[2] ALSHEIKH-ALI A A,KITSIOS G D,BALK E M,et al.The vulnerable atherosclerotic plaque:scope of the literature[J].Annals of Internal Medicine,2010,153(6):387-395.
[3] SCHELBERT E B,CAO J J,SIGURDSSON S,et al.Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adults[J].Jama,2012,308(9):890-896.
[4] KULLO I J,COOPER L T.Early identification of cardiovascular risk using genomics and proteomics[J].Nature Reviews Cardiology,2010,7(6):309-317.
[5] 于洁,冯毅,马根山.高龄冠心病合并糖尿病患者冠脉介入治疗的临床观察[J].现代医学,2012,40(6):51-54.
[6] LI N,LIU J Y,QIU H,et al.Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease[J].Congestive Heart Failure,2011,17(1):42-46.
[7] WISHART D S.Current progress in computational metabolomics[J].Briefings in Bioinformatics,2007,8(5):279-293.
[8] LAWTON K A,BROWN M V,ALEXANDER D,et al.Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics[J].Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration,2014,15(5-6):362-370.
[9] MINAMOTO Y,OTONI C C,STEELMAN S M,et al.Alteration of the fecal microbiota and serum metabolite profiles in dogs with idiopathic inflammatory bowel disease[J].Gut Microbes,2015,6(1):33-47.
[10] NAVARRETE A,ARMITAGE E G,MUSTEANU M,et al.Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer[J].Pharmacology Research & Perspectives,2014,2(6):e00067.
[11] RANKIN N J,PREISS D,WELSH P,et al.The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective[J].Atherosclerosis,2014,237(1):287-300.
[12] PARK J Y,LEE S H,SHIN M J,et al.Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction[J].PloS One,2015,10(8):e0135228.
[13] ATHERTON H J,BAILEY N J,ZHANG W,et al.A combined 1H-NMR spectroscopy-and mass spectrometry-based metabolomic study of the PPAR-α null mutant mouse defines profound systemic changes in metabolism linked to the metabolic syndrome[J].Physiological Genomics,2006,27(2):178-186.
[14] O'HAGAN S,DUNN W B,KNOWLES J D,et al.Closed-loop,multiobjective optimization of two-dimensional gas chromatography/mass spectrometry for serum metabolomics[J].Analytical Chemistry,2007,79(2):464-476.
[15] ALLEN J,DAVEY H M,BROADHURST D,et al.High-throughput classification of yeast mutants for functional genomics using metabolic footprinting[J].Nature Biotechnology,2003,21(6):692-696.
[16] 阿基业.代谢组学数据处理方法——主成分分析[J].中国临床药理学与治疗学,2010 (5):481-489.
[17] SHAH S H,BAIN J R,MUEHLBAUER M J,et al.Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events[J].Circ-Cardiovasc Genet,2010,3(2):207-214.
[18] MIAO H,CHEN H,ZHANG X,et al.Urinary metabolomics on the biochemical profiles in diet-induced hyperlipidemia rat using ultraperformance liquid chromatography coupled with quadrupole time-of-flight SYNAPT high-definition mass spectrometry[J].Journal of Analytical Methods in Chemistry,2014,2014:184162.
[19] KANG S M,PARK J C,SHIN M J,et al.1 H nuclear magnetic resonance based metabolic urinary profiling of patients with ischemic heart failure[J].Clinical Biochemistry,2011,44(4):293-299.
[20] WANG Z,KLIPFELL E,BENNETT B J,et al.Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease[J].Nature,2011,472(7341):57-63.
[21] SHAH S H,SUN J L,STEVENS R D,et al.Baseline metabolomic profiles predict cardiovascular events in patients at risk for coronary artery disease[J].Am Heart J,2012,163(5):844-850.
[22] PARK J Y,LEE S H,SHIN M J,et al.Alteration in metabolic signature and lipid metabolism in patients with angina pectoris and myocardial infarction[J].PLoS One,2015,10(8):e0135228.
[23] GANNA A,SALIHOVIC S,SUNDSTROM J,et al.Large-scale metabolomic profiling identifies novel biomarkers for incident coronary heart disease[J].PLoS Genet,2014,10(12): e1004801.
[24] FERNANDEZ C,SANDIN M,SAMPAIO J L,et al.Plasma lipid composition and risk of developing cardiovascular disease[J].PloS One,2013,8(8):e71846.
[25] LIU Y,JIA H,CHANG X,et al.The metabolic disturbances of isoproterenol induced myocardial infarction in rats based on a tissue targeted metabonomics[J].Molecular Bio Systems,2013,9(11):2823-2834.
[26] BALL D R,CRUICKSHANK R,CARR C A,et al.Metabolic imaging of acute and chronic infarction in the perfused rat heart using hyperpolarised [1-13C] pyruvate[J].NMR in Biomedicine,2013,26(11):1441-1450.
[27] JOVÉ M,AYALA V,RAMÍREZ-N AU'G ÑEZ O,et al.Lipidome and metabolome analyses reveal potential plasma biomarkers of early atheroma plaque formation in hamsters[J].Cardiovascular Research,2013,97(4):642-652.
[28] SUHRE K,SHIN S Y,PETERSEN A K,et al.Human metabolic individuali-ty in biomedical and pharmaceutical research[J].Nature,2011,477(7362):54-60.
[29] GIEGER C,GEISTLINGER L,ALTMAIER E,et al.Genetics meets metabolomics:a genome-wide association study of metabolite profiles in human serum[J].PLoS Genet,2008,4(11):e1000282.
[30] RIZZA S,COPETTI M,ROSSI C,et al.Metabolomics signature improves the prediction of cardiovascular events in elderly subjects[J].Atherosclerosis,2014,232(2):260-264.
[31] DU F,VIRTUE A,WANG H,et al.Metabolomic analyses for atherosclerosis,diabetes,and obesity[J].Biomarker Res,2013,1(1):17.